Axsome Therapeutics AXSM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's operating cash flow?
- Axsome Therapeutics (AXSM) reported operating cash flow of -$20.7M in Q1 2026.
- How has Axsome Therapeutics's operating cash flow changed year-over-year?
- Axsome Therapeutics's operating cash flow increased by 52.3% year-over-year, from -$43.38M to -$20.7M.
- What is the long-term trend for Axsome Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's operating cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$108.23M to -$94.45M.
- What does operating cash flow mean?
- The net cash generated or used by the company's day-to-day business.
- How do you interpret operating cash flow?
- Positive values indicate self-sustaining operations, while negative values indicate a reliance on external financing to fund operations.
- How does operating cash flow compare across companies?
- Critical for all companies; for clinical-stage biopharma, this is typically negative due to high R&D investment.